CryoLife, Inc. (NYSE:CRY) updated its FY17 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $0.40-0.43 for the period, compared to the Thomson Reuters consensus estimate of $0.41. The company issued revenue guidance of $184-185 million, compared to the consensus revenue estimate of $187.96 million.

A number of equities research analysts have weighed in on the stock. BidaskClub downgraded shares of CryoLife from a hold rating to a sell rating in a research report on Tuesday, August 1st. Zacks Investment Research downgraded shares of CryoLife from a buy rating to a sell rating in a research report on Wednesday, August 2nd. Lake Street Capital boosted their price objective on shares of CryoLife to $26.00 and gave the company a buy rating in a research report on Wednesday, October 11th. Finally, Canaccord Genuity reissued a buy rating and set a $25.00 price objective on shares of CryoLife in a research report on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $23.63.

Shares of CryoLife, Inc. (NYSE:CRY) traded up 0.50% during mid-day trading on Monday, reaching $20.10. 214,988 shares of the company’s stock traded hands. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $24.00. The company’s 50 day moving average is $21.74 and its 200 day moving average is $19.61. The company has a market cap of $672.26 million, a P/E ratio of 60.91 and a beta of 0.92.

CryoLife (NYSE:CRY) last posted its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $44.00 million for the quarter, compared to analyst estimates of $44.60 million. During the same quarter in the previous year, the firm posted $0.13 earnings per share. The business’s revenue was down 2.9% compared to the same quarter last year. On average, analysts predict that CryoLife, Inc. will post $0.42 EPS for the current fiscal year.

In related news, CEO James P. Mackin sold 125,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at approximately $8,768,761.99. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James Benson sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total transaction of $45,600.00. The disclosure for this sale can be found here. Insiders have sold 171,050 shares of company stock worth $3,769,825 over the last ninety days. 6.00% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History and Estimates for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with's FREE daily email newsletter.